Cellective BioTherapy is a biotechnology company that focuses on developing innovative therapies utilizing B cell-based solutions for cancer, autoimmune diseases, and immunodeficiency. Since its establishment in 2015, the company has been dedicated to creating cellular and monoclonal antibody-based platforms to address a range of health challenges. Their R&D efforts are centered on B cell-based cellular therapies intended for immunomodulation, immunodeficiency, and autoimmune conditions.
This forward-thinking startup's research extends to various medical areas, including cancer, diabetes, asthma, congenital and acquired immunodeficiency, and vaccine development. In June 2015, Cellective BioTherapy secured a significant $2.50M Angel Round investment from Eshelman Ventures, demonstrating strong investor confidence in the company's potential for medical innovation and impact.
